Table 3.

Summary of 10-year outcomes with reference to biologic markers.

Biologic Criterion			EFS			OS
Marker		n	Events	10y	p	Deaths	10y	p
MYCN	normal	133	21	84 ± 3	0.035	14	89 ± 3	0.008
	MNA	26	10	60 ± 10		9	64 ± 10
	hetMNA	4	0	100		0	100
SCAs	absent	52	7	87 ± 5	0.014	2	96 ± 3	<0.001
	present	56	20	64 ± 6		17	69 ± 6
1p	normal	89	14	84 ± 4	0.015	10	89 ± 3	0.004
	loss	33	12	64 ± 8		10	69 ± 8
1q	normal	91	18	81 ± 4	<0.001	10	89 ± 3	<0.001
	gain/loss	6	6	0		6	0
2p	normal	80	18	78 ± 5	0.702	11	86 ± 5	0.562
	gain	12	2	83 ± 11		2	83 ± 11
3p	normal	83	18	78 ± 5	0.007	11	87 ± 4	0.002
	loss	10	6	40 ± 15		5	50 ± 16
4p	normal	87	21	76 ± 5	0.512	14	87 ± 5	0.119
	loss	7	1	86 ± 13		0	100
11q	normal	80	15	81 ± 4	0.002	8	90 ± 3	<0.001
	loss	17	9	47 ± 12		9	47 ± 12
14q	normal	70	17	75 ± 5	0.971	12	83 ± 5	0.982
	loss	12	3	75 ± 13		2	83 ± 15
17q	normal	58	9	84 ± 5	0.006	3	95 ± 3	<0.001
	gain	38	16	58 ± 8		15	61 ± 8

10-year (10y) event-free survival (EFS) and overall survival (OS) according to the univariate analysis of biologic markers including MYCN amplification (MNA) and heterogeneous MNA (hetMNA), and presence or absence of segmental chromosomal alterations (SCAs).